Been a very lacklustre share over the last 5 years this one. Good dividend thoughGSK might be worth a punt. UK regulator approved this drug today. Shares haven't reacted yet.
Early data suggest GSK antibody treatment is effective against OmicronGlaxoSmithKline’s Covid-19 antibody treatment is likely to be able to tackle the Omicron coronavirus variant, according to early data from the company, despite rival drugs losing efficacy against the recently discovered strain.
The UK drugmaker and its partner Vir Biotechnology said on Thursday that early tests suggest the antibody treatment, called sotrovimab, is effective against Omicron’s key mutations. But the companies’ paper has not yet been peer-reviewed and they still need to complete lab tests of sotrovimab. The companies will provide an update by the end of 2021.
By contrast, early tests of Regeneron’s antibody treatment Ronapreve found the mutations in Omicron may hamper the drug’s ability to treat Covid-19.
Hal Barron, GSK’s chief scientific officer, said the company was working to expand access to the treatment worldwide.
“Though early, these pre-clinical data support our long-held view on the potential for sotrovimab to maintain its activity as the virus continues to mutate,” he said.
Separately on Thursday, the UK regulator approved the drug for high risk people with mild and moderate disease. The Medicines and Healthcare Products Regulatory Agency said it would work with GSK to establish if Omicron will have any impact on its efficacy.
Dr June Raine, MHRA chief executive said: “This is yet another therapeutic that has been shown to be effective at protecting those most vulnerable to Covid-19, and signals another significant step forward in our fight against this devastating disease.”